Evolving Data about Subtrochanteric Fractures and Bisphosphonates
Author:
- Elizabeth ShaneESElizabeth Shane
- 13 May 2010
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (19) , 1825-1827
Abstract
Osteoporosis, a skeletal disorder characterized by reduced bone strength that predisposes to an increased risk of fracture, affects 10 to 12 million people in the United States. In 2000, there were 9 million fractures worldwide, of which 1.6 million were hip fractures. Fractures are important because of their association with an increased rate of death, substantial morbidity, enormous costs, and devastating effects on independence and quality of life.Bisphosphonates, the major class of drugs used to treat osteoporosis,1,2 decrease osteoclast-mediated bone resorption and bone turnover markers and increase bone mineral density. They have been shown to reduce the risk . . .Keywords
This publication has 7 references indexed in Scilit:
- Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal FemurNew England Journal of Medicine, 2010
- Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort StudyJournal of Bone and Mineral Research, 2009
- Fragility fractures of the hip and femur: incidence and patient characteristicsOsteoporosis International, 2009
- Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal OsteoporosisThe American Journal of Medicine, 2009
- Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking AlendronateNew England Journal of Medicine, 2008
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporosis International, 2008
- Severely Suppressed Bone Turnover: A Potential Complication of Alendronate TherapyThe Journal of Clinical Endocrinology & Metabolism, 2005